Seeking Alpha

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, ...
PharmiWeb

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology (AAAAI) Annual MeetingResearch demonstrates the technology’s ability to identify ...
Seeking Alpha

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today ...
TechRadar

Affinity by Canva (2026) review: Three design tools in one, all for free - but is the software an Adobe-killer?

Canva’s Affinity is an impressive tool: its designers managed to cram three apps into one, and not turn it into a convoluted mess. Instead, the interface is clean and well designed, the tools are ...

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung ...

SAN ANTONIO, February 25, 2026--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum samples for lung cancer detection with CyPath Lung.
Nasdaq

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today ...
Yahoo Finance

Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study

SAN ANTONIO, Texas, February 17, 2026--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung ...
Nasdaq

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

bioAffinity Technologies: https://www.redchip.com/assets/access/biaf_access In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight ...
Business Wire

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

SAN ANTONIO, Texas--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, ...
Morningstar

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

View source version on businesswire.com: https://www.businesswire.com/news/home/20251114274995/en/ The articles, information, and content displayed on this webpage ...
Morningstar

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered ...
Business Wire

bioAffinity Technologies Announces Closing of $3.25 Million Offering

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today ...